Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BQ39
UPID:
DDX50_HUMAN
Alternative names:
DEAD box protein 50; Gu-beta; Nucleolar protein Gu2
Alternative UPACC:
Q9BQ39; Q5VX37; Q8WV76; Q9BWI8
Background:
ATP-dependent RNA helicase DDX50, also known as DEAD box protein 50, Gu-beta, and Nucleolar protein Gu2, plays a crucial role in RNA metabolism. This protein is involved in various RNA processes including ribosome biogenesis, mRNA splicing, and possibly RNA decay, showcasing its multifaceted role in cellular RNA management.
Therapeutic significance:
Understanding the role of ATP-dependent RNA helicase DDX50 could open doors to potential therapeutic strategies. Its involvement in fundamental RNA processes makes it a promising target for drug discovery, aiming to modulate RNA metabolism in disease conditions.